Inhibikase Therapeutics, Inc. (IKT)
NASDAQ: IKT · Real-Time Price · USD
2.310
0.00 (0.00%)
At close: Sep 16, 2026, 4:00 PM EDT
2.320
+0.010 (0.43%)
After-hours: Sep 16, 2026, 7:30 PM EDT
Inhibikase Therapeutics Employees
Inhibikase Therapeutics had 35 employees as of December 31, 2025. The number of employees increased by 19 or 118.75% compared to the previous year.
Employees
35
Change (1Y)
19
Growth (1Y)
118.75%
Revenue / Employee
n/a
Profits / Employee
-$1,732,486
Market Cap
420.59M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 35 | 19 | 118.75% | 35 | 0 |
| Dec 31, 2024 | 16 | 7 | 77.78% | 15 | 1 |
| Dec 31, 2023 | 9 | 2 | 28.57% | 8 | 1 |
| Dec 31, 2022 | 7 | 0 | - | 6 | 1 |
| Dec 31, 2021 | 7 | 4 | 133.33% | 6 | 1 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | - |
Related Stocks
| Company Name | Employees |
|---|---|
| ARS Pharmaceuticals | 200 |
| Cabaletta Bio | 158 |
| Kyverna Therapeutics | 149 |
| Artiva Biotherapeutics | 115 |
| C4 Therapeutics | 104 |
| Editas Medicine | 87 |
| Larimar Therapeutics | 71 |
| Rezolute | 68 |
IKT News
- 8 days ago - Inhibikase Therapeutics Slides: Corporate presentation - Filings
- 5 weeks ago - Inhibikase Therapeutics reports Q2 EPS (11c), consensus (9c) - TheFly
- 5 weeks ago - Inhibikase Therapeutics Announces Second Quarter 2026 Financial Results and Highlights Recent Activity - GlobeNewsWire
- 5 weeks ago - Inhibikase Therapeutics Earnings release: Q2 2026 - Filings
- 5 weeks ago - Inhibikase Therapeutics Quarterly report: Q2 2026 - Filings
- 7 weeks ago - Inhibikase Therapeutics IKT-001 gets Orphan Drug Designation from FDA - TheFly
- 7 weeks ago - Inhibikase Therapeutics Announces FDA Orphan Drug Designation Granted to IKT-001 for the Treatment of PAH - GlobeNewsWire
- 2 months ago - Inhibikase Therapeutics’ treatment of PAH granted FDA orphan designation - TheFly